GeneLink, Inc.

Equities

GNLKQ

US36870F1075

Healthcare Facilities & Services

Market Closed - OTC Markets Other stock markets 01:18:16 30/01/2024 am IST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	+900.00%

2015	GeneLink Inc. Emerged from Bankruptcy	CI
2015	Second Amended Reorganization Plan and Disclosure Statement Approved for GeneLink Inc.	CI

First Motion for Exclusivity Period Extension Approved For GeneLink Inc.

October 29, 2014 at 09:30 am IST

The US Bankruptcy Court granted an order for the extension of the exclusivity period for GeneLink Inc. on October 29, 2014. As per the order, the debtor's exclusivity period to solicit votes on its plan has been extended up to December 3, 2014.

Latest news about GeneLink, Inc.

GeneLink Inc. Emerged from Bankruptcy	10/15/10	CI
Second Amended Reorganization Plan and Disclosure Statement Approved for GeneLink Inc.	16/15/16	CI
Second Amended Reorganization Plan and Disclosure Statement Filed by GeneLink Inc.	29/14/29	CI
First Motion for Exclusivity Period Extension Approved For GeneLink Inc.	29/14/29	CI
First Amended Disclosure Statement Conditionally Approved for GeneLink Inc.	23/14/23	CI
First Amended Reorganization Plan and Disclosure Statement Filed by GeneLink Inc.	21/14/21	CI
First Motion for Exclusivity Period Extension Filed by GeneLink Inc.	14/14/14	CI
Reorganization Plan and Disclosure Statement Filed by GeneLink Inc.	13/14/13	CI
Amended DIP Financing Approved for GeneLink Inc.	28/14/28	CI
GeneLink Inc. will Change its Ticker to GNLK.Q from GNLK	30/14/30	CI
Interim DIP Financing Approved for GeneLink Inc.	28/14/28	CI
GeneLink Inc. Filed for Bankruptcy	18/14/18	CI
GeneLink, Inc. Appoints Michael G. Smith as Chief Operating Officer and Interim Chief Financial Officer	15/13/15	CI
GeneLink Inc. Announces Resignation of Two Directors	08/13/08	CI
Genelink Inc. Announces Board Changes	12/13/12	CI
GeneLink Inc. Announces Earnings Results for the Fiscal Year Ended December 31, 2012	04/13/04	CI
GeneLink Inc. announced that it expects to receive $0.60 million in funding.	04/13/04	CI
GeneLink Inc. Announces Executive Changes	12/13/12	CI
GeneLink Inc. Announces Executive Changes, Effective from July 13, 2012	17/12/17	CI
GeneLink Inc. announced that it expects to receive $1.50 million in funding.	20/12/20	CI
GeneLink Inc. Announces Earnings Results for the First Quarter Ended March 31, 2012	23/12/23	CI
GeneLink Inc. has Changed its Ticker to GNLK from GNLKE	16/12/16	CI
GeneLink Inc. Restates Unaudited Earnings Results for the Three Months Ended March 31, 2011, Second Quarter and Six Months Ended June 30, 2011 and Third Quarter and Nine Months Ended September 30, 2011	12/12/12	CI
GeneLink Inc. Reports Earnings Results for the Fiscal Year Ended December 31, 2011	11/12/11	CI
GeneLink Inc. has Changed its Ticker to GNLK.E from GNLK	19/12/19	CI

Chart GeneLink, Inc.

Duration

Period

More charts

Company Profile

Genelink, Inc. is a supplier of custom oligonucleotides. The Company offers a range of commercially available modifications, fluorescently labeled probes, and specialized probes, such as Molecular Beacons, TaqMan, and Fluorescence resonance energy transfer (FRET), as well as a variety of other molecular biology products, such as linkers, adaptors, deoxyribonucleic acid (DNA) purification and clean-up kits. The Companyâs product line of gene detection systems comprises reagents and reagent systems for scientists in the detection of genetic disorders. The Company focuses on triple repeat disorders, which include fragile x, myotonic dystrophy, huntington's disease. It also specializes in the synthesis of ribonucleic acid (RNA) modified oligos, RNA fluorescent probes with quenchers, chimeric oligos containing various combinations of DNA, 2'O methyl bases and phosphorothioate linkages. It serves various industries, including research institutes, pharmaceutical companies and hospitals.

Sector

Healthcare Facilities & Services

More about the company

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
GENELINK, INC.	+900.00%	2.65K
SONIC HEALTHCARE LIMITED	-24.13%	7.76B
RADNET, INC.	+67.56%	4.35B
DR. LAL PATHLABS LIMITED	+2.59%	2.67B
SYNLAB AG	-2.45%	2.64B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-47.56%	2.1B
NEOGENOMICS, INC.	-17.86%	1.73B
FLEURY S.A.	-19.62%	1.52B
METROPOLIS HEALTHCARE LIMITED	+12.59%	1.18B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-45.36%	1.11B

Medical & Diagnostic Laboratories